KRAS and non-small cell lung carcinoma: The demonstrated efficacy of sotorasib and adagrasib, the first mutant-selective covalent KRAS G12C inhibitors (KRASi) in KRAS G12C pretreated NSCLC, with response rates of 30-40%, led to approval by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA), marking a breakthrough for this drug category (16–19).